Dr. Sneha Ujjayani

Medical Oncology resident , Sri Shankara cancer hospital and research center ,
Bangalore

Intervention Post-Chemotherapy: Structured Exercise Significantly Extends Survival in Colon Cancer Patients

The final results of the Phase 3 CHALLENGE trial (CO.21) provide definitive evidence that a structured exercise program initiated after adjuvant chemotherapy significantly improves long-term outcomes for patients with resected stage II or III colon cancer.

Study Design and Patient Population

Between 2009 and 2024, 889 patients who had completed adjuvant chemotherapy within the previous 2 to 6 months were randomized to either

a 3-year structured exercise program (n=445) or health-education materials alone (n=444).

The exercise group received a guidebook and support from a certified consultant to increase recreational aerobic exercise by at least 10 MET-hours per week (roughly 45–60 minutes of brisk walking 3–4 times weekly).

Key Efficacy Findings

At a median follow-up of 7.9 years, the study reached its primary endpoint of disease-free survival (DFS).

Disease-Free Survival: The exercise group demonstrated a 28% reduction in the risk of disease recurrence, new primary cancer, or death (HR, 0.72; 95% CI, 0.55 to 0.94; P=0.02). The 5-year DFS was 80.3% for the exercise group versus 73.9% for the health-education group.

Overall Survival: Results also supported a survival benefit, with a 37% reduction in the risk of death (HR, 0.63; 95% CI, 0.43 to 0.94). The 8-year overall survival rate was 90.3% in the exercise group compared to 83.2% in the health-education group.

Recurrence Patterns: The benefit was largely driven by a reduction in liver recurrences and a decrease in second primary cancers, such as breast and prostate cancer.

Safety and Patient Functioning

While musculoskeletal adverse events were more common in the exercise group (18.5% vs. 11.5%), the intervention led to significant, sustained improvements in patient-reported physical functioning and objective cardiorespiratory fitness. Notably, the exercise did not significantly reduce body weight, suggesting the survival benefits may be linked to metabolic or immune-mediated mechanisms rather than weight loss.

Summary

This landmark study transitions exercise from a "lifestyle recommendation" to an evidence-based component of survivorship care. The magnitude of the benefit—a 6.4% absolute increase in 5-year DFS—is comparable to the gains seen with some adjuvant pharmacological therapies.

Practitioners should note that the trial specifically utilized a behavior-support program rather than just providing advice. The high adherence rates (83% in the initial phase) suggest that structured support is key to achieving these outcomes. While the study excluded patients with very early recurrences, the findings provide a robust rationale for integrating supervised physical activity programs into the standard of care for colon cancer survivors.